Intervention

ONC201

ClinicalTrials.gov intervention label

Clinical trials3

Recruiting1

Common conditions14

Lead sponsors shown3

Clinical trials

3 shown

ONC201 and Atezolizumab in Obesity-Driven Endometrial CancerNCT05542407 · 2023-10-23

ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial CarcinomaNCT03394027 · 2018-01-17

A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced CancerNCT02038699 · 2014-01-01

Common conditions

Endometrial Cancer2 Advanced Colorectal Cancer1 Advanced Glioblastoma1 Advanced Non-small Cell Lung Cancer1 Advanced Triple-negative Breast Cancer1 Carcinosarcoma1 Clear Cell Endometrial Carcinoma1 Endometrial Endometrioid Adenocarcinoma1 Endometrial Mixed Cell Adenocarcinoma1 Endometrioid Endometrial Cancer1 Hormone Receptor Positive, HER2 Negative Breast Cancer1 Metastasis1 Serous Adenocarcinoma of Endometrium (Diagnosis)1 Triple Negative Breast Cancer1

Leading sponsors

Jazz Pharmaceuticals1 National Cancer Institute (NCI)1 UNC Lineberger Comprehensive Cancer Center1

Trial status mix

COMPLETED1

RECRUITING1

WITHDRAWN1

Phase mix

PHASE12

PHASE22

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.